Skip to main content
. 2022 Jan 1;13(3):869–876. doi: 10.7150/jca.65145

Figure 2.

Figure 2

Low PARP-1 expression levels were associated with significantly shorter overall survival in patients with stage II and III gastric cancer (A). The disease-free survival was differentiated on the basis of PARP-1 expression (B).